XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

US lab operator Quest Diagnostics to launch bird flu test at end of October



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US lab operator Quest Diagnostics to launch bird flu test at end of October</title></head><body>

Oct 23 -Lab operator Quest Diagnostics DGX.N said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus.


WHY IT'S IMPORTANT

The spread of bird flu among dairy herds and infections of 27 people this year have alarmed some public health experts.

More than 100 million U.S. chickens, turkeys and other birds have been eliminated by the virus since the outbreak began in 2022.

The CDC says that this year, there have been 91 cases of the Oropouche virus, which spreads primarily through bites from midges as well as from some mosquitoes.

Last month, the CDC issued a health alert to notify clinicians and public health authorities of an increase in Oropouche virus cases in the Americas region that has caused two deaths so far this year.


CONTEXT

Besides Quest, the CDC is working with four laboratory companies, including Aegis, ARUP, Ginkgo BioWorks DNA.N and Labcorp LH.N, to develop tests for health outbreaks.

This will support the country's preparedness for these threats by ensuring a commercial laboratory provider is able to supplement public health laboratories in case of an outbreak in people.

The CDC contract also provides Quest with funds to maintain testing readiness, such as for adequate supplies of equipment and chemical reagents used to perform the tests.


WHAT'S NEXT

Quest's bird flu test will be available with a prescription.

Its laboratory in San Juan Capistrano, California, which developed the test, will also conduct the test.

The test is intended to be performed using respiratory specimens or specimens of the outer membrane of eyes collected from people suspected of having the virus, or who meet the CDC's testing criteria.



Reporting by Puyaan Singh in Bengaluru; Editing by Savio D'Souza

</body></html>

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.